Literature DB >> 10971175

Thymidylate synthase expression in epithelial ovarian cancer: relationship with thymidine phosphorylase expression and prognosis.

R Fujiwaki1, K Hata, K Nakayama, M Fukumoto, K Miyazaki.   

Abstract

OBJECTIVE: Thymidylate synthase (TS) and thymidine phosphorylase (TP) are important enzymes involved in the de novo DNA synthesis and the salvage pathways for pyrimidine, respectively. Our purpose was to determine whether the gene expression of TS together with TP correlate with prognosis in epithelial ovarian cancer.
METHODS: TS gene expression was analyzed by reverse transcription-polymerase chain reaction in 20 samples from normal ovaries and 56 epithelial ovarian cancers previously studied regarding TP gene expression. TS and TP protein localization was examined by immunohistochemistry.
RESULTS: TS gene expression was significantly higher in epithelial ovarian cancer than in normal ovaries (p = 0.001). In patients with epithelial ovarian cancer, TS gene expression did not correlate with patient age, clinical stage, histologic type, or histologic grade. High TS gene expression (> median) significantly correlated with a poorer survival (p = 0.02). No significant correlation between TS and TP gene expression and different immunoreactivity patterns were found. Combined analysis of TS and TP gene expression demonstrated that the relative risk of death for tumors with high TS and high TP expression was greater than that for either only high TS or high TP gene expression (p = 0.002).
CONCLUSION: TS and TP combined may indicate a poor prognosis for patients with epithelial ovarian cancer. Copyright 2000 S. Karger AG, Basel.

Entities:  

Mesh:

Substances:

Year:  2000        PMID: 10971175     DOI: 10.1159/000012153

Source DB:  PubMed          Journal:  Oncology        ISSN: 0030-2414            Impact factor:   2.935


  3 in total

Review 1.  Strategies for Delivery of siRNAs to Ovarian Cancer Cells.

Authors:  Rossella Farra; Matea Maruna; Francesca Perrone; Mario Grassi; Fabio Benedetti; Marianna Maddaloni; Maguie El Boustani; Salvo Parisi; Flavio Rizzolio; Giancarlo Forte; Fabrizio Zanconati; Maja Cemazar; Urska Kamensek; Barbara Dapas; Gabriele Grassi
Journal:  Pharmaceutics       Date:  2019-10-22       Impact factor: 6.321

2.  4-Methylumbelliferone inhibits ovarian cancer growth by suppressing thymidine phosphorylase expression.

Authors:  Ryosuke Tamura; Yoshihito Yokoyama; Hidemi Yoshida; Tadaatsu Imaizumi; Hideki Mizunuma
Journal:  J Ovarian Res       Date:  2014-10-11       Impact factor: 4.234

3.  Anticancer activity of the intraperitoneal-delivered DFP-10825, the cationic liposome-conjugated RNAi molecule targeting thymidylate synthase, on peritoneal disseminated ovarian cancer xenograft model.

Authors:  Kenzo Iizuka; Cheng Jin; Kokoro Eshima; Mei Hua Hong; Kiyoshi Eshima; Masakazu Fukushima
Journal:  Drug Des Devel Ther       Date:  2018-03-29       Impact factor: 4.162

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.